nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—PTGS2—esophageal cancer	0.345	0.54	CbGaD
Pomalidomide—ABCB1—esophageal cancer	0.294	0.46	CbGaD
Pomalidomide—PTGS2—Cisplatin—esophageal cancer	0.0618	0.648	CbGbCtD
Pomalidomide—ABCB1—Cisplatin—esophageal cancer	0.0204	0.214	CbGbCtD
Pomalidomide—ABCB1—Methotrexate—esophageal cancer	0.0132	0.139	CbGbCtD
Pomalidomide—Pneumocystis jirovecii pneumonia—Methotrexate—esophageal cancer	0.00509	0.0414	CcSEcCtD
Pomalidomide—Neutropenic sepsis—Capecitabine—esophageal cancer	0.00495	0.0402	CcSEcCtD
Pomalidomide—Bronchopneumonia—Capecitabine—esophageal cancer	0.00393	0.032	CcSEcCtD
Pomalidomide—Thromboembolic event—Capecitabine—esophageal cancer	0.00319	0.0259	CcSEcCtD
Pomalidomide—Peripheral sensory neuropathy—Capecitabine—esophageal cancer	0.003	0.0244	CcSEcCtD
Pomalidomide—Thromboembolic event—Methotrexate—esophageal cancer	0.00237	0.0193	CcSEcCtD
Pomalidomide—Tumour lysis syndrome—Methotrexate—esophageal cancer	0.0023	0.0187	CcSEcCtD
Pomalidomide—Developmental delay—Capecitabine—esophageal cancer	0.00226	0.0184	CcSEcCtD
Pomalidomide—Congenital anomaly—Capecitabine—esophageal cancer	0.00226	0.0184	CcSEcCtD
Pomalidomide—Febrile neutropenia—Cisplatin—esophageal cancer	0.00193	0.0157	CcSEcCtD
Pomalidomide—Altered state of consciousness—Capecitabine—esophageal cancer	0.00186	0.0151	CcSEcCtD
Pomalidomide—Thalidomide—PTGS1—esophageal cancer	0.00179	0.3	CrCbGaD
Pomalidomide—Lenalidomide—PTGS2—esophageal cancer	0.00171	0.286	CrCbGaD
Pomalidomide—Lymphopenia—Capecitabine—esophageal cancer	0.00168	0.0136	CcSEcCtD
Pomalidomide—Night sweats—Capecitabine—esophageal cancer	0.00159	0.0129	CcSEcCtD
Pomalidomide—Lenalidomide—ABCB1—esophageal cancer	0.00145	0.243	CrCbGaD
Pomalidomide—Platelet count decreased—Capecitabine—esophageal cancer	0.00144	0.0117	CcSEcCtD
Pomalidomide—Febrile neutropenia—Capecitabine—esophageal cancer	0.00143	0.0116	CcSEcCtD
Pomalidomide—Deep vein thrombosis—Capecitabine—esophageal cancer	0.00141	0.0115	CcSEcCtD
Pomalidomide—Infection—Carboplatin—esophageal cancer	0.00141	0.0114	CcSEcCtD
Pomalidomide—Embolism—Capecitabine—esophageal cancer	0.00134	0.0109	CcSEcCtD
Pomalidomide—Hypercalcaemia—Capecitabine—esophageal cancer	0.00123	0.01	CcSEcCtD
Pomalidomide—Pain—Carboplatin—esophageal cancer	0.00121	0.00984	CcSEcCtD
Pomalidomide—Hyperkalaemia—Cisplatin—esophageal cancer	0.00114	0.0093	CcSEcCtD
Pomalidomide—Body temperature increased—Carboplatin—esophageal cancer	0.00112	0.0091	CcSEcCtD
Pomalidomide—Neuropathy—Cisplatin—esophageal cancer	0.00109	0.00889	CcSEcCtD
Pomalidomide—Febrile neutropenia—Methotrexate—esophageal cancer	0.00106	0.00863	CcSEcCtD
Pomalidomide—Deep vein thrombosis—Methotrexate—esophageal cancer	0.00105	0.00854	CcSEcCtD
Pomalidomide—Thalidomide—PTGS2—esophageal cancer	0.00102	0.171	CrCbGaD
Pomalidomide—Embolism—Methotrexate—esophageal cancer	0.000995	0.00809	CcSEcCtD
Pomalidomide—Hyperbilirubinaemia—Capecitabine—esophageal cancer	0.000943	0.00767	CcSEcCtD
Pomalidomide—Hypocalcaemia—Capecitabine—esophageal cancer	0.000937	0.00762	CcSEcCtD
Pomalidomide—Cardiac failure congestive—Cisplatin—esophageal cancer	0.000932	0.00758	CcSEcCtD
Pomalidomide—CRBN—bronchus—esophageal cancer	0.000906	0.133	CbGeAlD
Pomalidomide—Interstitial lung disease—Methotrexate—esophageal cancer	0.000902	0.00734	CcSEcCtD
Pomalidomide—Bone pain—Capecitabine—esophageal cancer	0.000896	0.00728	CcSEcCtD
Pomalidomide—Pulmonary embolism—Capecitabine—esophageal cancer	0.000858	0.00698	CcSEcCtD
Pomalidomide—Hyponatraemia—Cisplatin—esophageal cancer	0.000848	0.0069	CcSEcCtD
Pomalidomide—TNF—lymph node—esophageal cancer	0.000836	0.123	CbGeAlD
Pomalidomide—Depressed level of consciousness—Capecitabine—esophageal cancer	0.000828	0.00674	CcSEcCtD
Pomalidomide—CRBN—trachea—esophageal cancer	0.000813	0.119	CbGeAlD
Pomalidomide—Neuropathy—Capecitabine—esophageal cancer	0.000806	0.00655	CcSEcCtD
Pomalidomide—Blood creatinine increased—Cisplatin—esophageal cancer	0.000791	0.00644	CcSEcCtD
Pomalidomide—Dehydration—Cisplatin—esophageal cancer	0.000786	0.00639	CcSEcCtD
Pomalidomide—Hypokalaemia—Cisplatin—esophageal cancer	0.000769	0.00625	CcSEcCtD
Pomalidomide—Breast disorder—Cisplatin—esophageal cancer	0.000763	0.00621	CcSEcCtD
Pomalidomide—Nasopharyngitis—Cisplatin—esophageal cancer	0.000756	0.00614	CcSEcCtD
Pomalidomide—Sepsis—Capecitabine—esophageal cancer	0.000745	0.00605	CcSEcCtD
Pomalidomide—Hyperbilirubinaemia—Methotrexate—esophageal cancer	0.000702	0.00571	CcSEcCtD
Pomalidomide—CRBN—digestive system—esophageal cancer	0.0007	0.103	CbGeAlD
Pomalidomide—Pancytopenia—Cisplatin—esophageal cancer	0.000693	0.00564	CcSEcCtD
Pomalidomide—Atrial fibrillation—Capecitabine—esophageal cancer	0.000657	0.00534	CcSEcCtD
Pomalidomide—Renal failure—Cisplatin—esophageal cancer	0.00064	0.0052	CcSEcCtD
Pomalidomide—Pulmonary embolism—Methotrexate—esophageal cancer	0.000639	0.00519	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Cisplatin—esophageal cancer	0.000638	0.00519	CcSEcCtD
Pomalidomide—Hyponatraemia—Capecitabine—esophageal cancer	0.000625	0.00508	CcSEcCtD
Pomalidomide—Pain in extremity—Capecitabine—esophageal cancer	0.000623	0.00506	CcSEcCtD
Pomalidomide—Depressed level of consciousness—Methotrexate—esophageal cancer	0.000617	0.00502	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Cisplatin—esophageal cancer	0.000616	0.00501	CcSEcCtD
Pomalidomide—Urinary retention—Capecitabine—esophageal cancer	0.000592	0.00482	CcSEcCtD
Pomalidomide—CRBN—lung—esophageal cancer	0.000584	0.0857	CbGeAlD
Pomalidomide—Blood creatinine increased—Capecitabine—esophageal cancer	0.000583	0.00474	CcSEcCtD
Pomalidomide—Dehydration—Capecitabine—esophageal cancer	0.000579	0.00471	CcSEcCtD
Pomalidomide—Urinary tract disorder—Cisplatin—esophageal cancer	0.000577	0.00469	CcSEcCtD
Pomalidomide—Connective tissue disorder—Cisplatin—esophageal cancer	0.000574	0.00467	CcSEcCtD
Pomalidomide—Urethral disorder—Cisplatin—esophageal cancer	0.000573	0.00466	CcSEcCtD
Pomalidomide—Dry skin—Capecitabine—esophageal cancer	0.000571	0.00464	CcSEcCtD
Pomalidomide—Hypokalaemia—Capecitabine—esophageal cancer	0.000567	0.00461	CcSEcCtD
Pomalidomide—Breast disorder—Capecitabine—esophageal cancer	0.000563	0.00458	CcSEcCtD
Pomalidomide—Nasopharyngitis—Capecitabine—esophageal cancer	0.000557	0.00453	CcSEcCtD
Pomalidomide—Sepsis—Methotrexate—esophageal cancer	0.000554	0.00451	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000549	0.00447	CcSEcCtD
Pomalidomide—Muscular weakness—Capecitabine—esophageal cancer	0.000549	0.00447	CcSEcCtD
Pomalidomide—Cardiac disorder—Cisplatin—esophageal cancer	0.000542	0.00441	CcSEcCtD
Pomalidomide—Mediastinal disorder—Cisplatin—esophageal cancer	0.000527	0.00428	CcSEcCtD
Pomalidomide—Bronchitis—Capecitabine—esophageal cancer	0.000518	0.00421	CcSEcCtD
Pomalidomide—Pancytopenia—Capecitabine—esophageal cancer	0.000511	0.00416	CcSEcCtD
Pomalidomide—Malnutrition—Cisplatin—esophageal cancer	0.000509	0.00414	CcSEcCtD
Pomalidomide—Neutropenia—Capecitabine—esophageal cancer	0.000503	0.00409	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.0005	0.00407	CcSEcCtD
Pomalidomide—Weight increased—Capecitabine—esophageal cancer	0.00049	0.00398	CcSEcCtD
Pomalidomide—Muscle spasms—Cisplatin—esophageal cancer	0.000489	0.00398	CcSEcCtD
Pomalidomide—Weight decreased—Capecitabine—esophageal cancer	0.000487	0.00396	CcSEcCtD
Pomalidomide—Hyperglycaemia—Capecitabine—esophageal cancer	0.000486	0.00395	CcSEcCtD
Pomalidomide—Pneumonia—Capecitabine—esophageal cancer	0.000483	0.00393	CcSEcCtD
Pomalidomide—Infestation—Capecitabine—esophageal cancer	0.00048	0.0039	CcSEcCtD
Pomalidomide—Infestation NOS—Capecitabine—esophageal cancer	0.00048	0.0039	CcSEcCtD
Pomalidomide—Tremor—Cisplatin—esophageal cancer	0.000477	0.00388	CcSEcCtD
Pomalidomide—Renal failure—Capecitabine—esophageal cancer	0.000472	0.00384	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Capecitabine—esophageal cancer	0.00047	0.00383	CcSEcCtD
Pomalidomide—Anaemia—Cisplatin—esophageal cancer	0.00047	0.00382	CcSEcCtD
Pomalidomide—Urinary tract infection—Capecitabine—esophageal cancer	0.000467	0.00379	CcSEcCtD
Pomalidomide—Leukopenia—Cisplatin—esophageal cancer	0.000455	0.0037	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000454	0.00369	CcSEcCtD
Pomalidomide—Epistaxis—Capecitabine—esophageal cancer	0.000453	0.00368	CcSEcCtD
Pomalidomide—Anxiety—Cisplatin—esophageal cancer	0.000432	0.00351	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00043	0.0035	CcSEcCtD
Pomalidomide—Urinary tract disorder—Capecitabine—esophageal cancer	0.000425	0.00346	CcSEcCtD
Pomalidomide—Oedema peripheral—Capecitabine—esophageal cancer	0.000424	0.00345	CcSEcCtD
Pomalidomide—Connective tissue disorder—Capecitabine—esophageal cancer	0.000423	0.00344	CcSEcCtD
Pomalidomide—Urethral disorder—Capecitabine—esophageal cancer	0.000422	0.00343	CcSEcCtD
Pomalidomide—Breast disorder—Methotrexate—esophageal cancer	0.000419	0.00341	CcSEcCtD
Pomalidomide—Infection—Cisplatin—esophageal cancer	0.000413	0.00335	CcSEcCtD
Pomalidomide—Nervous system disorder—Cisplatin—esophageal cancer	0.000407	0.00331	CcSEcCtD
Pomalidomide—Thrombocytopenia—Cisplatin—esophageal cancer	0.000407	0.00331	CcSEcCtD
Pomalidomide—Skin disorder—Cisplatin—esophageal cancer	0.000403	0.00328	CcSEcCtD
Pomalidomide—Hyperhidrosis—Cisplatin—esophageal cancer	0.000401	0.00326	CcSEcCtD
Pomalidomide—Cardiac disorder—Capecitabine—esophageal cancer	0.0004	0.00325	CcSEcCtD
Pomalidomide—CRBN—lymph node—esophageal cancer	0.0004	0.0586	CbGeAlD
Pomalidomide—Angiopathy—Capecitabine—esophageal cancer	0.000391	0.00318	CcSEcCtD
Pomalidomide—Mediastinal disorder—Capecitabine—esophageal cancer	0.000388	0.00316	CcSEcCtD
Pomalidomide—Chills—Capecitabine—esophageal cancer	0.000387	0.00314	CcSEcCtD
Pomalidomide—Pancytopenia—Methotrexate—esophageal cancer	0.000381	0.00309	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000378	0.00308	CcSEcCtD
Pomalidomide—Mental disorder—Capecitabine—esophageal cancer	0.000377	0.00307	CcSEcCtD
Pomalidomide—Malnutrition—Capecitabine—esophageal cancer	0.000375	0.00305	CcSEcCtD
Pomalidomide—Neutropenia—Methotrexate—esophageal cancer	0.000375	0.00305	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000372	0.00303	CcSEcCtD
Pomalidomide—Dyspnoea—Cisplatin—esophageal cancer	0.00037	0.00301	CcSEcCtD
Pomalidomide—Back pain—Capecitabine—esophageal cancer	0.000363	0.00295	CcSEcCtD
Pomalidomide—Decreased appetite—Cisplatin—esophageal cancer	0.000361	0.00294	CcSEcCtD
Pomalidomide—Muscle spasms—Capecitabine—esophageal cancer	0.000361	0.00293	CcSEcCtD
Pomalidomide—Pneumonia—Methotrexate—esophageal cancer	0.000359	0.00292	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000358	0.00292	CcSEcCtD
Pomalidomide—Infestation NOS—Methotrexate—esophageal cancer	0.000357	0.00291	CcSEcCtD
Pomalidomide—Infestation—Methotrexate—esophageal cancer	0.000357	0.00291	CcSEcCtD
Pomalidomide—Pain—Cisplatin—esophageal cancer	0.000355	0.00289	CcSEcCtD
Pomalidomide—Tremor—Capecitabine—esophageal cancer	0.000351	0.00286	CcSEcCtD
Pomalidomide—Renal failure—Methotrexate—esophageal cancer	0.000351	0.00286	CcSEcCtD
Pomalidomide—Anaemia—Capecitabine—esophageal cancer	0.000347	0.00282	CcSEcCtD
Pomalidomide—Feeling abnormal—Cisplatin—esophageal cancer	0.000342	0.00278	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000338	0.00275	CcSEcCtD
Pomalidomide—Epistaxis—Methotrexate—esophageal cancer	0.000337	0.00274	CcSEcCtD
Pomalidomide—Vertigo—Capecitabine—esophageal cancer	0.000337	0.00274	CcSEcCtD
Pomalidomide—Leukopenia—Capecitabine—esophageal cancer	0.000336	0.00273	CcSEcCtD
Pomalidomide—Body temperature increased—Cisplatin—esophageal cancer	0.000328	0.00267	CcSEcCtD
Pomalidomide—Cough—Capecitabine—esophageal cancer	0.000327	0.00266	CcSEcCtD
Pomalidomide—Arthralgia—Capecitabine—esophageal cancer	0.000319	0.0026	CcSEcCtD
Pomalidomide—Anxiety—Capecitabine—esophageal cancer	0.000318	0.00259	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000317	0.00258	CcSEcCtD
Pomalidomide—Urinary tract disorder—Methotrexate—esophageal cancer	0.000317	0.00258	CcSEcCtD
Pomalidomide—Urethral disorder—Methotrexate—esophageal cancer	0.000314	0.00256	CcSEcCtD
Pomalidomide—Confusional state—Capecitabine—esophageal cancer	0.000309	0.00251	CcSEcCtD
Pomalidomide—Hypersensitivity—Cisplatin—esophageal cancer	0.000306	0.00249	CcSEcCtD
Pomalidomide—Infection—Capecitabine—esophageal cancer	0.000304	0.00247	CcSEcCtD
Pomalidomide—Nervous system disorder—Capecitabine—esophageal cancer	0.0003	0.00244	CcSEcCtD
Pomalidomide—Thrombocytopenia—Capecitabine—esophageal cancer	0.0003	0.00244	CcSEcCtD
Pomalidomide—Asthenia—Cisplatin—esophageal cancer	0.000298	0.00242	CcSEcCtD
Pomalidomide—Cardiac disorder—Methotrexate—esophageal cancer	0.000298	0.00242	CcSEcCtD
Pomalidomide—Skin disorder—Capecitabine—esophageal cancer	0.000297	0.00242	CcSEcCtD
Pomalidomide—Hyperhidrosis—Capecitabine—esophageal cancer	0.000296	0.00241	CcSEcCtD
Pomalidomide—Angiopathy—Methotrexate—esophageal cancer	0.000291	0.00237	CcSEcCtD
Pomalidomide—Mediastinal disorder—Methotrexate—esophageal cancer	0.000289	0.00235	CcSEcCtD
Pomalidomide—Chills—Methotrexate—esophageal cancer	0.000288	0.00234	CcSEcCtD
Pomalidomide—Diarrhoea—Cisplatin—esophageal cancer	0.000284	0.00231	CcSEcCtD
Pomalidomide—Mental disorder—Methotrexate—esophageal cancer	0.000281	0.00229	CcSEcCtD
Pomalidomide—Malnutrition—Methotrexate—esophageal cancer	0.000279	0.00227	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000279	0.00227	CcSEcCtD
Pomalidomide—Insomnia—Capecitabine—esophageal cancer	0.000277	0.00225	CcSEcCtD
Pomalidomide—Dyspnoea—Capecitabine—esophageal cancer	0.000273	0.00222	CcSEcCtD
Pomalidomide—Back pain—Methotrexate—esophageal cancer	0.00027	0.0022	CcSEcCtD
Pomalidomide—Decreased appetite—Capecitabine—esophageal cancer	0.000266	0.00216	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000264	0.00215	CcSEcCtD
Pomalidomide—Vomiting—Cisplatin—esophageal cancer	0.000264	0.00215	CcSEcCtD
Pomalidomide—Fatigue—Capecitabine—esophageal cancer	0.000264	0.00215	CcSEcCtD
Pomalidomide—Rash—Cisplatin—esophageal cancer	0.000262	0.00213	CcSEcCtD
Pomalidomide—Pain—Capecitabine—esophageal cancer	0.000262	0.00213	CcSEcCtD
Pomalidomide—Constipation—Capecitabine—esophageal cancer	0.000262	0.00213	CcSEcCtD
Pomalidomide—Dermatitis—Cisplatin—esophageal cancer	0.000262	0.00213	CcSEcCtD
Pomalidomide—Anaemia—Methotrexate—esophageal cancer	0.000258	0.0021	CcSEcCtD
Pomalidomide—Feeling abnormal—Capecitabine—esophageal cancer	0.000252	0.00205	CcSEcCtD
Pomalidomide—Vertigo—Methotrexate—esophageal cancer	0.000251	0.00204	CcSEcCtD
Pomalidomide—PTGS2—epithelium—esophageal cancer	0.00025	0.0367	CbGeAlD
Pomalidomide—Leukopenia—Methotrexate—esophageal cancer	0.00025	0.00203	CcSEcCtD
Pomalidomide—Nausea—Cisplatin—esophageal cancer	0.000247	0.00201	CcSEcCtD
Pomalidomide—PTGS2—bronchus—esophageal cancer	0.000247	0.0362	CbGeAlD
Pomalidomide—Cough—Methotrexate—esophageal cancer	0.000244	0.00198	CcSEcCtD
Pomalidomide—Body temperature increased—Capecitabine—esophageal cancer	0.000242	0.00197	CcSEcCtD
Pomalidomide—PTGS2—smooth muscle tissue—esophageal cancer	0.000241	0.0354	CbGeAlD
Pomalidomide—Arthralgia—Methotrexate—esophageal cancer	0.000238	0.00193	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000236	0.00192	CcSEcCtD
Pomalidomide—CYP1A2—digestive system—esophageal cancer	0.00023	0.0337	CbGeAlD
Pomalidomide—Confusional state—Methotrexate—esophageal cancer	0.00023	0.00187	CcSEcCtD
Pomalidomide—Infection—Methotrexate—esophageal cancer	0.000226	0.00184	CcSEcCtD
Pomalidomide—Hypersensitivity—Capecitabine—esophageal cancer	0.000226	0.00183	CcSEcCtD
Pomalidomide—Nervous system disorder—Methotrexate—esophageal cancer	0.000223	0.00182	CcSEcCtD
Pomalidomide—Thrombocytopenia—Methotrexate—esophageal cancer	0.000223	0.00181	CcSEcCtD
Pomalidomide—PTGS2—trachea—esophageal cancer	0.000221	0.0325	CbGeAlD
Pomalidomide—Skin disorder—Methotrexate—esophageal cancer	0.000221	0.0018	CcSEcCtD
Pomalidomide—Hyperhidrosis—Methotrexate—esophageal cancer	0.00022	0.00179	CcSEcCtD
Pomalidomide—Asthenia—Capecitabine—esophageal cancer	0.00022	0.00179	CcSEcCtD
Pomalidomide—Pruritus—Capecitabine—esophageal cancer	0.000217	0.00176	CcSEcCtD
Pomalidomide—Diarrhoea—Capecitabine—esophageal cancer	0.000209	0.0017	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000208	0.00169	CcSEcCtD
Pomalidomide—Insomnia—Methotrexate—esophageal cancer	0.000206	0.00168	CcSEcCtD
Pomalidomide—Dyspnoea—Methotrexate—esophageal cancer	0.000203	0.00165	CcSEcCtD
Pomalidomide—Dizziness—Capecitabine—esophageal cancer	0.000202	0.00165	CcSEcCtD
Pomalidomide—Decreased appetite—Methotrexate—esophageal cancer	0.000198	0.00161	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000197	0.0016	CcSEcCtD
Pomalidomide—Fatigue—Methotrexate—esophageal cancer	0.000196	0.0016	CcSEcCtD
Pomalidomide—Pain—Methotrexate—esophageal cancer	0.000195	0.00158	CcSEcCtD
Pomalidomide—Vomiting—Capecitabine—esophageal cancer	0.000195	0.00158	CcSEcCtD
Pomalidomide—Rash—Capecitabine—esophageal cancer	0.000193	0.00157	CcSEcCtD
Pomalidomide—Dermatitis—Capecitabine—esophageal cancer	0.000193	0.00157	CcSEcCtD
Pomalidomide—CYP1A2—lung—esophageal cancer	0.000192	0.0282	CbGeAlD
Pomalidomide—Headache—Capecitabine—esophageal cancer	0.000192	0.00156	CcSEcCtD
Pomalidomide—PTGS2—digestive system—esophageal cancer	0.000191	0.0279	CbGeAlD
Pomalidomide—Feeling abnormal—Methotrexate—esophageal cancer	0.000188	0.00153	CcSEcCtD
Pomalidomide—Nausea—Capecitabine—esophageal cancer	0.000182	0.00148	CcSEcCtD
Pomalidomide—Body temperature increased—Methotrexate—esophageal cancer	0.00018	0.00146	CcSEcCtD
Pomalidomide—Hypersensitivity—Methotrexate—esophageal cancer	0.000168	0.00137	CcSEcCtD
Pomalidomide—CYP3A4—digestive system—esophageal cancer	0.000166	0.0244	CbGeAlD
Pomalidomide—Asthenia—Methotrexate—esophageal cancer	0.000163	0.00133	CcSEcCtD
Pomalidomide—Pruritus—Methotrexate—esophageal cancer	0.000161	0.00131	CcSEcCtD
Pomalidomide—PTGS2—lung—esophageal cancer	0.000159	0.0233	CbGeAlD
Pomalidomide—Diarrhoea—Methotrexate—esophageal cancer	0.000156	0.00127	CcSEcCtD
Pomalidomide—ABCB1—epithelium—esophageal cancer	0.000155	0.0227	CbGeAlD
Pomalidomide—Dizziness—Methotrexate—esophageal cancer	0.000151	0.00123	CcSEcCtD
Pomalidomide—Vomiting—Methotrexate—esophageal cancer	0.000145	0.00118	CcSEcCtD
Pomalidomide—Rash—Methotrexate—esophageal cancer	0.000144	0.00117	CcSEcCtD
Pomalidomide—Dermatitis—Methotrexate—esophageal cancer	0.000144	0.00117	CcSEcCtD
Pomalidomide—Headache—Methotrexate—esophageal cancer	0.000143	0.00116	CcSEcCtD
Pomalidomide—ABCB1—trachea—esophageal cancer	0.000137	0.0201	CbGeAlD
Pomalidomide—Nausea—Methotrexate—esophageal cancer	0.000135	0.0011	CcSEcCtD
Pomalidomide—ABCB1—digestive system—esophageal cancer	0.000118	0.0173	CbGeAlD
Pomalidomide—PTGS2—lymph node—esophageal cancer	0.000109	0.016	CbGeAlD
Pomalidomide—ABCB1—lung—esophageal cancer	9.84e-05	0.0144	CbGeAlD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	7.09e-05	0.000547	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	7.05e-05	0.000544	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—KMT2D—esophageal cancer	7.04e-05	0.000544	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—SMAD4—esophageal cancer	7.01e-05	0.000541	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—EP300—esophageal cancer	7e-05	0.00054	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	6.96e-05	0.000537	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—CYP1B1—esophageal cancer	6.92e-05	0.000535	CbGpPWpGaD
Pomalidomide—CYP1A2—Metapathway biotransformation—CYP1B1—esophageal cancer	6.83e-05	0.000527	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	6.82e-05	0.000526	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	6.78e-05	0.000524	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—AQP3—esophageal cancer	6.76e-05	0.000522	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CCND1—esophageal cancer	6.74e-05	0.00052	CbGpPWpGaD
Pomalidomide—ABCB1—lymph node—esophageal cancer	6.73e-05	0.00987	CbGeAlD
Pomalidomide—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	6.71e-05	0.000518	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	6.68e-05	0.000516	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	6.63e-05	0.000512	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—MYC—esophageal cancer	6.59e-05	0.000508	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	6.57e-05	0.000507	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—CYP19A1—esophageal cancer	6.51e-05	0.000503	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—PIK3CA—esophageal cancer	6.51e-05	0.000502	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—esophageal cancer	6.5e-05	0.000502	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	6.49e-05	0.000501	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	6.49e-05	0.000501	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—EGFR—esophageal cancer	6.44e-05	0.000497	CbGpPWpGaD
Pomalidomide—CYP1A2—Metapathway biotransformation—CYP19A1—esophageal cancer	6.42e-05	0.000496	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—esophageal cancer	6.35e-05	0.000491	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—esophageal cancer	6.35e-05	0.000491	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	6.29e-05	0.000485	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	6.22e-05	0.00048	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	6.21e-05	0.00048	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	6.19e-05	0.000478	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—SLC52A3—esophageal cancer	6.18e-05	0.000477	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—BLVRB—esophageal cancer	6.18e-05	0.000477	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	5.94e-05	0.000459	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	5.81e-05	0.000449	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—esophageal cancer	5.77e-05	0.000445	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	5.53e-05	0.000427	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—KDR—esophageal cancer	5.48e-05	0.000423	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FKBP1A—esophageal cancer	5.46e-05	0.000422	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—TP53—esophageal cancer	5.41e-05	0.000417	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—MYC—esophageal cancer	5.4e-05	0.000417	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MET—esophageal cancer	5.36e-05	0.000414	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	5.34e-05	0.000413	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	5.34e-05	0.000412	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—WIF1—esophageal cancer	5.34e-05	0.000412	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—DOCK2—esophageal cancer	5.34e-05	0.000412	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—EGFR—esophageal cancer	5.28e-05	0.000408	CbGpPWpGaD
Pomalidomide—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	5.27e-05	0.000407	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—SLC10A2—esophageal cancer	5.26e-05	0.000406	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CA1—esophageal cancer	5.26e-05	0.000406	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	5.19e-05	0.0004	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—NOTCH1—esophageal cancer	5.16e-05	0.000399	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	5.05e-05	0.000389	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	5.02e-05	0.000388	CbGpPWpGaD
Pomalidomide—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	4.96e-05	0.000383	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CSNK1A1—esophageal cancer	4.93e-05	0.00038	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	4.92e-05	0.000379	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	4.88e-05	0.000377	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CA2—esophageal cancer	4.81e-05	0.000371	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	4.7e-05	0.000363	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—CREBBP—esophageal cancer	4.68e-05	0.000361	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	4.58e-05	0.000354	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	4.51e-05	0.000348	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PLCE1—esophageal cancer	4.47e-05	0.000345	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ADH7—esophageal cancer	4.47e-05	0.000345	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—GNG7—esophageal cancer	4.46e-05	0.000344	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TP53—esophageal cancer	4.44e-05	0.000343	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	4.43e-05	0.000342	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	4.42e-05	0.000341	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	4.41e-05	0.00034	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	4.39e-05	0.000339	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—SLC52A3—esophageal cancer	4.38e-05	0.000338	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—BLVRB—esophageal cancer	4.38e-05	0.000338	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	4.22e-05	0.000326	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—ELMO1—esophageal cancer	4.14e-05	0.000319	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—GSTO1—esophageal cancer	4.04e-05	0.000312	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TPI1—esophageal cancer	4.04e-05	0.000312	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	3.94e-05	0.000304	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—ERBB2—esophageal cancer	3.92e-05	0.000303	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ADH1B—esophageal cancer	3.92e-05	0.000303	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—ALDOB—esophageal cancer	3.88e-05	0.000299	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	3.78e-05	0.000292	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—TYMP—esophageal cancer	3.75e-05	0.000289	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—GAPDH—esophageal cancer	3.73e-05	0.000288	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HIST1H2BM—esophageal cancer	3.73e-05	0.000288	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CA1—esophageal cancer	3.73e-05	0.000288	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—SLC10A2—esophageal cancer	3.73e-05	0.000288	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	3.68e-05	0.000284	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	3.68e-05	0.000284	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CYP26A1—esophageal cancer	3.64e-05	0.000281	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	3.6e-05	0.000278	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	3.6e-05	0.000278	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ALOX15—esophageal cancer	3.55e-05	0.000274	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—SLC52A3—esophageal cancer	3.5e-05	0.00027	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—BLVRB—esophageal cancer	3.5e-05	0.00027	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CA2—esophageal cancer	3.41e-05	0.000263	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—TPI1—esophageal cancer	3.39e-05	0.000261	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GSTO1—esophageal cancer	3.39e-05	0.000261	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—XIAP—esophageal cancer	3.3e-05	0.000255	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	3.25e-05	0.000251	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ALDOB—esophageal cancer	3.25e-05	0.000251	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—EP300—esophageal cancer	3.19e-05	0.000246	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ADH7—esophageal cancer	3.17e-05	0.000245	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PLCE1—esophageal cancer	3.17e-05	0.000245	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	3.14e-05	0.000243	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	3.13e-05	0.000241	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GAPDH—esophageal cancer	3.13e-05	0.000241	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	3.12e-05	0.000241	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CRABP1—esophageal cancer	3.1e-05	0.000239	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—B2M—esophageal cancer	3.07e-05	0.000237	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	3.02e-05	0.000233	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	2.99e-05	0.000231	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CA1—esophageal cancer	2.97e-05	0.00023	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—SLC10A2—esophageal cancer	2.97e-05	0.00023	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GNG7—esophageal cancer	2.95e-05	0.000227	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—ENO1—esophageal cancer	2.94e-05	0.000227	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PSME1—esophageal cancer	2.9e-05	0.000224	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PSME2—esophageal cancer	2.9e-05	0.000224	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CALR—esophageal cancer	2.78e-05	0.000215	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ADH1B—esophageal cancer	2.78e-05	0.000214	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ALDH2—esophageal cancer	2.76e-05	0.000213	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CA2—esophageal cancer	2.72e-05	0.00021	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—EGFR—esophageal cancer	2.72e-05	0.00021	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	2.72e-05	0.00021	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—BLVRB—esophageal cancer	2.7e-05	0.000208	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—SLC52A3—esophageal cancer	2.7e-05	0.000208	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FBXW7—esophageal cancer	2.69e-05	0.000207	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	2.66e-05	0.000205	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—TYMP—esophageal cancer	2.66e-05	0.000205	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GSTT1—esophageal cancer	2.63e-05	0.000203	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	2.61e-05	0.000201	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CYP2A6—esophageal cancer	2.6e-05	0.0002	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.59e-05	0.0002	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP26A1—esophageal cancer	2.58e-05	0.000199	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	2.55e-05	0.000197	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ADH7—esophageal cancer	2.53e-05	0.000195	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PLCE1—esophageal cancer	2.53e-05	0.000195	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ALOX15—esophageal cancer	2.52e-05	0.000194	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	2.5e-05	0.000193	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PTGS1—esophageal cancer	2.46e-05	0.00019	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ENO1—esophageal cancer	2.46e-05	0.00019	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PSME1—esophageal cancer	2.43e-05	0.000187	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PSME2—esophageal cancer	2.43e-05	0.000187	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GSTO1—esophageal cancer	2.4e-05	0.000185	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—TPI1—esophageal cancer	2.4e-05	0.000185	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ALDOB—esophageal cancer	2.3e-05	0.000178	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CA1—esophageal cancer	2.3e-05	0.000177	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—SLC10A2—esophageal cancer	2.3e-05	0.000177	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ADH1B—esophageal cancer	2.22e-05	0.000171	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GAPDH—esophageal cancer	2.22e-05	0.000171	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	2.21e-05	0.000171	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CRABP1—esophageal cancer	2.2e-05	0.00017	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TGFBR2—esophageal cancer	2.17e-05	0.000168	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	2.14e-05	0.000165	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—TYMP—esophageal cancer	2.12e-05	0.000164	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CA2—esophageal cancer	2.1e-05	0.000162	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CYP1B1—esophageal cancer	2.09e-05	0.000162	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GNG7—esophageal cancer	2.09e-05	0.000161	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP26A1—esophageal cancer	2.06e-05	0.000159	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—SMAD4—esophageal cancer	2.06e-05	0.000159	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ALOX15—esophageal cancer	2.01e-05	0.000155	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CYP19A1—esophageal cancer	1.97e-05	0.000152	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ALDH2—esophageal cancer	1.96e-05	0.000151	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PLCE1—esophageal cancer	1.95e-05	0.000151	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ADH7—esophageal cancer	1.95e-05	0.000151	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTO1—esophageal cancer	1.92e-05	0.000148	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—TPI1—esophageal cancer	1.92e-05	0.000148	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GSTT1—esophageal cancer	1.86e-05	0.000144	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP2A6—esophageal cancer	1.84e-05	0.000142	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ALDOB—esophageal cancer	1.84e-05	0.000142	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—HMOX1—esophageal cancer	1.8e-05	0.000139	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GAPDH—esophageal cancer	1.77e-05	0.000137	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.76e-05	0.000136	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CRABP1—esophageal cancer	1.75e-05	0.000135	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ENO1—esophageal cancer	1.74e-05	0.000135	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PTGS1—esophageal cancer	1.74e-05	0.000135	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.74e-05	0.000135	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ABCB1—esophageal cancer	1.72e-05	0.000133	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PSME2—esophageal cancer	1.72e-05	0.000133	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PSME1—esophageal cancer	1.72e-05	0.000133	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ADH1B—esophageal cancer	1.71e-05	0.000132	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HIF1A—esophageal cancer	1.68e-05	0.00013	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GNG7—esophageal cancer	1.67e-05	0.000129	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—TYMP—esophageal cancer	1.64e-05	0.000126	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP26A1—esophageal cancer	1.59e-05	0.000123	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ALDH2—esophageal cancer	1.56e-05	0.000121	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ALOX15—esophageal cancer	1.55e-05	0.00012	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NOS2—esophageal cancer	1.53e-05	0.000118	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NOTCH1—esophageal cancer	1.52e-05	0.000117	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTT1—esophageal cancer	1.49e-05	0.000115	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP1B1—esophageal cancer	1.48e-05	0.000115	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTO1—esophageal cancer	1.48e-05	0.000114	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—TPI1—esophageal cancer	1.48e-05	0.000114	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP2A6—esophageal cancer	1.47e-05	0.000113	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.46e-05	0.000113	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ALDOB—esophageal cancer	1.42e-05	0.000109	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP19A1—esophageal cancer	1.39e-05	0.000108	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ENO1—esophageal cancer	1.39e-05	0.000108	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PTGS1—esophageal cancer	1.39e-05	0.000108	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CREBBP—esophageal cancer	1.38e-05	0.000106	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PSME2—esophageal cancer	1.37e-05	0.000106	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PSME1—esophageal cancer	1.37e-05	0.000106	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GAPDH—esophageal cancer	1.37e-05	0.000105	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CRABP1—esophageal cancer	1.35e-05	0.000104	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.3e-05	0.000101	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GNG7—esophageal cancer	1.29e-05	9.93e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—HMOX1—esophageal cancer	1.27e-05	9.82e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NOS3—esophageal cancer	1.23e-05	9.51e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ALDH2—esophageal cancer	1.21e-05	9.31e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.2e-05	9.25e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP1B1—esophageal cancer	1.18e-05	9.14e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CREBBP—esophageal cancer	1.15e-05	8.89e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—ERBB2—esophageal cancer	1.15e-05	8.89e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTT1—esophageal cancer	1.15e-05	8.85e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP2A6—esophageal cancer	1.13e-05	8.75e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP19A1—esophageal cancer	1.11e-05	8.6e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ENO1—esophageal cancer	1.07e-05	8.3e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PTGS1—esophageal cancer	1.07e-05	8.3e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PSME2—esophageal cancer	1.06e-05	8.18e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PSME1—esophageal cancer	1.06e-05	8.18e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—NOS3—esophageal cancer	1.03e-05	7.96e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—HMOX1—esophageal cancer	1.02e-05	7.84e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	9.97e-06	7.69e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CDKN1A—esophageal cancer	9.84e-06	7.6e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ABCB1—esophageal cancer	9.75e-06	7.53e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—EP300—esophageal cancer	9.37e-06	7.23e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP1B1—esophageal cancer	9.14e-06	7.06e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP19A1—esophageal cancer	8.59e-06	6.63e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CREBBP—esophageal cancer	8.16e-06	6.3e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MYC—esophageal cancer	8.16e-06	6.3e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—EGFR—esophageal cancer	7.98e-06	6.16e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—EP300—esophageal cancer	7.84e-06	6.06e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—HMOX1—esophageal cancer	7.84e-06	6.05e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ABCB1—esophageal cancer	7.53e-06	5.81e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	7.37e-06	5.69e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NOS3—esophageal cancer	7.31e-06	5.64e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PIK3CA—esophageal cancer	6.93e-06	5.35e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PTGS2—esophageal cancer	6.69e-06	5.16e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CREBBP—esophageal cancer	6.52e-06	5.03e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NOS3—esophageal cancer	5.84e-06	4.5e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PIK3CA—esophageal cancer	5.8e-06	4.48e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—EP300—esophageal cancer	5.56e-06	4.29e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PTGS2—esophageal cancer	5.34e-06	4.12e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CREBBP—esophageal cancer	5.03e-06	3.88e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NOS3—esophageal cancer	4.5e-06	3.48e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—EP300—esophageal cancer	4.44e-06	3.43e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PTGS2—esophageal cancer	4.12e-06	3.18e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PIK3CA—esophageal cancer	4.11e-06	3.18e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—EP300—esophageal cancer	3.43e-06	2.64e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PIK3CA—esophageal cancer	3.28e-06	2.53e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PIK3CA—esophageal cancer	2.53e-06	1.96e-05	CbGpPWpGaD
